FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2585867912> ?p ?o ?g. }

• W2585867912 abstract "Abstract Background. Gemtuzumab ozogamicin (GO, Mylotarg®) is a humanized calicheamicin-conjugated monoclonal antibody targeted to the CD33 antigen present on myeloblasts. A 28% response rate in acute myeloblastic leukaemia (AML) in first relapse was reported in phase 2 single agent trials using Mylotarg at a dose of 9 mg/m2 for two doses at 14 days interval. Significant hepatotoxicity was observed and an increased risk (up to 60%) of developing veno-occlusive disease (VOD) was also reported in patients receiving stem cell transplantation (SCT) after GO exposure. Risk of VOD was correlated with a short interval, less than 3,5 months from GO administration to SCT. We report here the feasibility of an intensive consolidation therapy followed by autologous or allogeneic SCT in patients with AML in complete remission after a reduced and fractionated salvage therapy with GO. Patients and methods. We retrospectively collected the results from 10 consecutive patients (median age 47 years; 18 years to 62 years) treated in 4 haematological centers. All patients received 3 infusions of GO 3 mg/m2/d at day 1, day 4 and day 7 during the induction course. Consolidation modalities and conditioning regimens before HSCT were adapted in each center. Results. Eight patients were in relapse (first relapse, n=4; second and subsequent relapses, n=4) and 2 were primary refractory to induction therapy. After GO salvage therapy, 6 patients achieved a complete remission (CR) and 4 a CR without normalization of the platelets counts (CRp). A grade 1 toxicity and a non severe VOD were recorded during salvage therapy. Consolidation therapy was administered in 6 cases (based on Ara-C chemotherapy in 5 cases and GO administration (3 mg/m2 day 1) in 1 case). Five patients received an allogeneic SCT (genoidentical donors n=2, phenoidentical donors n=3, one of those after a non myeloablative conditioning regimen) and five patients received an autologous SCT after a conditioning regimen with busulfan and melphalan. Median interval between the last chemotherapy and the graft was 47 days (16 to 61 days) and median interval from the last dose of GO and the graft was 108 days (16 to 221 days). Three cases (30%) of hepatic toxicity were recorded (grade 1, n=1; grade 2, n=1; grade 3, n=1), including 2 cases with VOD (20%), one of them confirmed by liver biopsy. The two patients with VOD were successfully treated with defibrotide and normalization of the hepatic tests was obtained. In both cases, the conditioning regimen was TBI/EDX and the interval from the last GO infusion to SCT was short (30 days and 16 days). Of note, the patient who experienced hepatic toxicity during the fractionated induction course did not experienced hepatic toxicity during the intensive SCT phase. Overall, median DFS and OS post SCT were 6.4 months and 8.6 months respectively. Conclusion. This retrospective study argues in favour of a lower hepatotoxicity with fractionated doses of GO leading to a lower risk of VOD when stem cell transplant is used as post remission therapy." @default.
• W2585867912 created "2017-02-10" @default.
• W2585867912 creator A5000436961 @default.
• W2585867912 creator A5009196800 @default.
• W2585867912 creator A5019451763 @default.
• W2585867912 creator A5026922298 @default.
• W2585867912 creator A5052564121 @default.
• W2585867912 creator A5058825074 @default.
• W2585867912 creator A5064103067 @default.
• W2585867912 creator A5075272745 @default.
• W2585867912 date "2005-11-16" @default.
• W2585867912 modified "2023-09-27" @default.
• W2585867912 title "Low Incidence of Hepatic Veno-Occlusive Disease after Fractionated Doses of Mylotarg and Autologous or Allogeneic Stem Cell Transplantation." @default.
• W2585867912 doi "https://doi.org/10.1182/blood.v106.11.5300.5300" @default.
• W2585867912 hasPublicationYear "2005" @default.
• W2585867912 type Work @default.
• W2585867912 sameAs 2585867912 @default.
• W2585867912 citedByCount "0" @default.
• W2585867912 crossrefType "journal-article" @default.
• W2585867912 hasAuthorship W2585867912A5000436961 @default.
• W2585867912 hasAuthorship W2585867912A5009196800 @default.
• W2585867912 hasAuthorship W2585867912A5019451763 @default.
• W2585867912 hasAuthorship W2585867912A5026922298 @default.
• W2585867912 hasAuthorship W2585867912A5052564121 @default.
• W2585867912 hasAuthorship W2585867912A5058825074 @default.
• W2585867912 hasAuthorship W2585867912A5064103067 @default.
• W2585867912 hasAuthorship W2585867912A5075272745 @default.
• W2585867912 hasConcept C10205521 @default.
• W2585867912 hasConcept C126322002 @default.
• W2585867912 hasConcept C141071460 @default.
• W2585867912 hasConcept C176290653 @default.
• W2585867912 hasConcept C2776694085 @default.
• W2585867912 hasConcept C2777408962 @default.
• W2585867912 hasConcept C2778245361 @default.
• W2585867912 hasConcept C2778623314 @default.
• W2585867912 hasConcept C2778729363 @default.
• W2585867912 hasConcept C2780775027 @default.
• W2585867912 hasConcept C2780895475 @default.
• W2585867912 hasConcept C28328180 @default.
• W2585867912 hasConcept C2911091166 @default.
• W2585867912 hasConcept C54355233 @default.
• W2585867912 hasConcept C71924100 @default.
• W2585867912 hasConcept C86803240 @default.
• W2585867912 hasConcept C90924648 @default.
• W2585867912 hasConceptScore W2585867912C10205521 @default.
• W2585867912 hasConceptScore W2585867912C126322002 @default.
• W2585867912 hasConceptScore W2585867912C141071460 @default.
• W2585867912 hasConceptScore W2585867912C176290653 @default.
• W2585867912 hasConceptScore W2585867912C2776694085 @default.
• W2585867912 hasConceptScore W2585867912C2777408962 @default.
• W2585867912 hasConceptScore W2585867912C2778245361 @default.
• W2585867912 hasConceptScore W2585867912C2778623314 @default.
• W2585867912 hasConceptScore W2585867912C2778729363 @default.
• W2585867912 hasConceptScore W2585867912C2780775027 @default.
• W2585867912 hasConceptScore W2585867912C2780895475 @default.
• W2585867912 hasConceptScore W2585867912C28328180 @default.
• W2585867912 hasConceptScore W2585867912C2911091166 @default.
• W2585867912 hasConceptScore W2585867912C54355233 @default.
• W2585867912 hasConceptScore W2585867912C71924100 @default.
• W2585867912 hasConceptScore W2585867912C86803240 @default.
• W2585867912 hasConceptScore W2585867912C90924648 @default.
• W2585867912 hasLocation W25858679121 @default.
• W2585867912 hasOpenAccess W2585867912 @default.
• W2585867912 hasPrimaryLocation W25858679121 @default.
• W2585867912 hasRelatedWork W1983249075 @default.
• W2585867912 hasRelatedWork W2159659043 @default.
• W2585867912 hasRelatedWork W2169298590 @default.
• W2585867912 hasRelatedWork W2329587176 @default.
• W2585867912 hasRelatedWork W2377951221 @default.
• W2585867912 hasRelatedWork W2585867912 @default.
• W2585867912 hasRelatedWork W3089686118 @default.
• W2585867912 hasRelatedWork W3093044015 @default.
• W2585867912 hasRelatedWork W3214113889 @default.
• W2585867912 hasRelatedWork W2396862260 @default.
• W2585867912 isParatext "false" @default.
• W2585867912 isRetracted "false" @default.
• W2585867912 magId "2585867912" @default.
• W2585867912 workType "article" @default.